BioStock: Saniona’s clinical and regulatory progress during H1

Saniona’s first half of the year has resulted in both clinical and regulatory advancements. During H1, the company initiated a phase I study with SAN711 for the treatment of rare neuropathic diseases and also received two orphan drug classifications from the FDA in the two rare diseases hypothalamic obesity and Prader-Willi syndrome with the drug candidate Tesomet and is preparing to start two phase 2b trials before the end of this year.

Read the full article about Saniona at biostock.se:

https://www.biostock.se/en/2021/08/sanionas-clinical-and-regulatory-progress-during-h1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se